Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis?: A Real-World Study in China.

已完结 10 由何曼慈发布于 2026/6/8 14:28:40

DOI:10.1089/derm.2024.0014
作者：Jiling Zhu,?Hanwen Wu,?Yahui Ye,?Qiuyang Xu,?Junyi Shao,?Zicheng Bai,?Yiwen Zhou,?Zhenyan Li,?Jingjing Liu,?Zhiming Li
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1089/derm.2024.0014

Sage

Abstract： Background: The efficacy and safety of upadacitinib and dupilumab for atopic Dermatitis® (AD) in adolescent patients have been proven in clinical trials. However, few daily practice studies

应助信息

8小时前

亮露

2678f828630411f190d134735aa3bc31.pdf 已采纳

8小时前

Book学术机器人

2026/6/8 14:28:40 未找到该文献，机器人已退出，请等待人工下载

2026/6/8 14:28:40 Book学术AI机器人收到请求，开始寻找文献

2026/6/8 14:28:40 已向机器人发送请求

8小时前

何曼慈发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Taylor & FrancisSynthesis and Insecticidal Activity of Sesquilignan Analogs with 2-Alkyl-6-methoxy-3-(3,4-methylenedioxyphenyl)-1,4-benzodioxanyl Group